semaj83/ctmatch_classification huggingface dataset:
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-89.0,  Clostridium Difficile Infection Is able to read and sign a consent form Is from ≥18 to <90 years of age Has diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device Tests positive for Clostridium difficile If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study  Has toxic megacolon and/or known small bowel ileus Has received treatment with intravenous immune globulin (IVIG) within the past 30 days Has received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study Has received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working Has received an investigational vaccine against Clostridium difficile Has received an investigational product containing monoclonal antibodies against toxin A or B within 180 days Has more than 2 episodes of CDAD within 90 days Has had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months (this does not appendectomy or cholecystectomy) Has a history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis Is unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Watery Diarrhea Dysentery/Febrile Diarrhea Active duty military or military beneficiary, 18 years-old or older. 2. Presence of acute diarrhea (3 or more stools in 24 hours or 2 or more stools in 24 hours and associated symptoms such as nausea, vomiting, abdominal cramps or tenesmus) and <96 hours duration. 3. Eligible for ambulatory management. 4. Able to comply with follow-up procedures. 5. Will remain in country for at least 7 days  Allergy to rifamycins, quinolones, macrolides, or loperamide (not including mild gastrointestinal upset). 2. Antibiotic therapy in the 72 hours prior to presentation (excluding malaria prophylaxis with mefloquine, malarone, chloroquine/proguanil, or doxycycline). 3. Concomitant medications with known drug-drug interactions with any of the study drugs (includes theophylline, digoxin, and warfarin). 4. History of seizures (relative contraindication to quinolones) 5. Positive pregnancy test at presentation (contraindicated with fluoroquinolone therapy). All female subjects will be administered a urine pregnancy test prior to enrollment. 6. Presence of symptoms >96 hours prior to initiating treatment. 7. Use of >4 mg loperamide or use of any amount of loperamide for greater than 24 hours prior to enrollment
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Diabetes Obesity Osteoporosis Inflammation danish caucasian ethnicity informed consent normal fasting plasma glucose normal HbA1c (<6 %) normal serum lipids normal thyroid function normal danish diet non-smoking normal stool habits  known bone disease liver disease (ALAT or ASAT >2 upper normal value) kidney disease (serum creatinine >130 μM) anaemia BMI <18.5 kg/m2 or BMI >25 kg/m2 known gastrointestinal disease (including prior bariatric surgery,lactose -intolerance, celiac disease, inflammatory bowel disease) or known familial disposition for lactose intolerance, celiac disease, inflammatory bowel disease antibiotic treatment within 6 months prior to study including malaria prophylaxis medication which cannot be on hold for the study period contraindications against/allergy towards the used antibiotics (including prior allergic reactions related to beta-lactam antibiotics, aminoglycosides or vancomycin)
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 19.0-75.0,  Diarrhea Predominant Irritable Bowel Syndrome willing to consent/undergo necessary procedures between the age of 19 and 75 years diarrhea predominant irritable bowel syndrome (satisfied with Rome II criteria)  uncontrolled hypertension (Blood pressure > 180/110 mmHg) uncontrolled diabetes mellitus (FBS > 200 mg/dL) malignancy, cerebrovascular disease, cardiovascular disease history of abdominal surgery except appendectomy and hernia repair inflammatory bowel disease clinically or laboratory-confirmed gastroenteritis the use of motility drug or dietary fiber supplement in 2 weeks serum Cr > 2 x Upper normal limit AST or ALT > 2 x Upper normal limit Pregnancy, Lactating woman
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Metabolic Acidosis End stage renal disease  Neoplastic diseases Autoimmune diseases Decompensation class III-IV Uncontrollable hypertension Amputation of the limbs Previous ictus cerebri Neobladder, ureterosigmoidostomy Sever acidosis with bicarbonate < 18 mEq/l Use of calcium carbonate (relative factor: patients who used to take this drug and suspended it before the beginning of the 3-month run-in period can be included in the study)
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Constipation Constipation Patient has completed a colonoscopy according to the American Gastroenterological Association with no clinically significant findings Patient has successfully completed protocol procedures (with no clinically significant findings) Patient meets protocol for Chronic Constipation(CC): < 3 bowel movements per week and reports one or more of the following symptoms for at least 12 weeks: 1. Straining during more than 25% of BMs 2. Lumpy or hard stools during more than 25% of BMs 3. Sensation of incomplete evacuation during more than 25% of BMs Patient demonstrates continued chronic constipation and bloating through Pretreatment Period Patient is compliant with Interactive voice response System (IVRS)  Patient has a history of loose or watery stools Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS) Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility Patient has any protocol-excluded or clinically significant medical or surgical history that would limit the patient's ability to complete or participate in this clinical trial or could confound the study assessments
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Gastroparesis Nausea Vomiting Abdominal Pain Participants will be at least 18 years old and able to provide informed consent Participants will have symptoms of idiopathic gastroparesis for at least 6 months duration prior to enrollment with documented abnormal solid phase gastric emptying scintigraphy  Gastroparesis due to: diabetes, medication (e.g. post-chemotherapy), iatrogenic post-surgical gastroparesis, and severe neurologic conditions such as Parkinson's disease known to be associated with gastroparesis An active eating disorder Participants currently lactating, or preparing to conceive will also be excluded A history of inflammatory bowel disease Known bowel obstruction, or strictures
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pancreatic Neuroendocrine Tumors (pNET) Unresectable or metastatic, histologically confirmed low or intermediate grade pancreatic neuroendocrine tumor with radiological evidence of disease progression since last treatment Refractory disease to treatment with mTOR inhibitor Measurable disease per Version 1.1 using Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Prior or concurrent therapy with SSA is permitted; a stable dose at least 2 months prior to study start and must continue on the stable dose while receiving study treatment; SSA is not considered as a systemic treatment WHO PS ≤ 1 Adequate bone marrow function or organ function  Previous treatment with any PI3K or AKT inhibitor Discontinuation prior mTOR inhibitor therapy due to toxicity Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma Radiotherapy, or major surgery within 4 weeks prior to study treatment start Hepatic artery embolization or cryoablation/ radiofrequency ablation of hepatic metastasis within 2 months of study treatment start More than 3 prior systemic treatment regimens (including cytotoxic chemotherapy, targeted therapy, immunotherapy)
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Heart Failure Diagnosis of heart failure (stage C chronic HF confirmed by echocardiography and clinical evaluation) years of age or greater able to speak and read English telephone access in home Stable pharmacologic therapy per guidelines for past 30 days  clinical evidence of decompensated HF unstable angina pectoris myocardial infarction, coronary artery bypass surgery, or biventricular pacemaker within the past 6 weeks orthopedic or neuromuscular disorders preventing participation in aerobic exercise and strength/resistance training participation in 3 times per week aerobic exercise during the past 8 weeks cardiopulmonary stress test results that preclude safe exercise training plans to move more than 50 miles from the exercise site within the next year peak oxygen uptake (pVO2) in women>21mL kg min and in men >24mLkg min planned or current pregnancy
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anemia Hematopoietic/Lymphoid Cancer Lymphopenia Neutropenia Thrombocytopenia No evidence of active disease as measured by staging studies pertinent to the particular diagnosis within 1 month of the CD 34+ boost 2. Full donor chimerism as manifested by a ≥ 90% donor peripheral blood total, MNC, and T cell chimerism result on the last two studies prior to the planned CD 34+ boost, with the second study performed within 1 month of the infusion. 3. HHV-6 and CMV negative by PCR for at least 1 month prior to the CD 34+ boost as measured by at least 2 assays within the month timeframe 4. ANC of < 1000 10^6/L or maintenance of an ANC ≥ 1000 10^6/L only with white cell growth factor support 5. Requirement for red cell transfusion to maintain a hemoglobin of ≥ 9.0 g/dL 6. Requirement for red cell transfusion to avoid symptomatic anemia in patients with hemoglobin values of ≤ 11.0 g/dL 7. Requirement for platelet transfusion to maintain a platelet count of ≥ 20 10^9/L 8. Requirement for platelet transfusion to avoid bleeding in patients with platelet counts ≤ 50 109/L 9. No signs of active acute GVHD (excluding stages I-II skin GVHD)
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Critically Ill Adults Ventilated >24 Hours in Intensive Care they have received invasive mechanical ventilation for at least 24 hours, and have been in ICU less than 72 hours the treating clinician expects the patient to still be receiving invasive mechanical ventilation in the ICU the day after tomorrow  Age less than 18 years old Patient has a proven or suspected acute primary brain process that is likely to result in global impairment of conscious level or cognition, such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury after cardiac arrest or asphyxiation Second or subsequent admission to ICU during a single hospital admission Patient does not speak English Patient has proven or suspected primary myopathic or neurological process associated with prolonged weakness, such as Guillain-Barre syndrome Death is deemed imminent and inevitable Inability to walk without assistance prior to the acute illness that is associated with admission to ICU (use of a cane or walker not an exclusion) Cognitive impairment prior to the acute illness that is associated with admission to ICU (refer data dictionary) Any written "Rest In Bed" or non-weight bearing medical order such as may occur with hip fracture, unstable spine or pelvis, pathological fracture
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Mental Illness Chronic Medical Illness a diagnosis of schizophrenia/ schizoaffective disorder bipolar disorder major depression with psychotic features post traumatic stress disorder or psychosis not otherwise specified (NOS) age between 18 and 80 chart documented presence of at least one of the following chronic medical conditions a respiratory condition (e.g. asthma, COPD) diabetes arthritis  Severe or profound mental retardation Because participants must be able to attend the intervention if assigned to either condition, we will also require potential participants to verify their availability during screening Participation in current ongoing study 'Reducing Internalized Stigma in People with Serious Mental Illness"